552 related articles for article (PubMed ID: 31430398)
1. At the bench: Engineering the next generation of cancer vaccines.
Shae D; Baljon JJ; Wehbe M; Becker KW; Sheehy TL; Wilson JT
J Leukoc Biol; 2020 Oct; 108(4):1435-1453. PubMed ID: 31430398
[TBL] [Abstract][Full Text] [Related]
2. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
4. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH
Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145
[TBL] [Abstract][Full Text] [Related]
5. Amplified Cancer Immunotherapy of a Surface-Engineered Antigenic Microparticle Vaccine by Synergistically Modulating Tumor Microenvironment.
Zhao H; Zhao B; Wu L; Xiao H; Ding K; Zheng C; Song Q; Sun L; Wang L; Zhang Z
ACS Nano; 2019 Nov; 13(11):12553-12566. PubMed ID: 31689085
[TBL] [Abstract][Full Text] [Related]
6. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
[No Abstract] [Full Text] [Related]
7. Methods for improving the immunogenicity and efficacy of cancer vaccines.
Pilla L; Ferrone S; Maccalli C
Expert Opin Biol Ther; 2018 Jul; 18(7):765-784. PubMed ID: 29874943
[TBL] [Abstract][Full Text] [Related]
8. In situ antitumor vaccination: Targeting the tumor microenvironment.
Li H; Yu J; Wu Y; Shao B; Wei X
J Cell Physiol; 2020 Jul; 235(7-8):5490-5500. PubMed ID: 32030759
[TBL] [Abstract][Full Text] [Related]
9. Advances in Therapeutic Cancer Vaccines.
Wong KK; Li WA; Mooney DJ; Dranoff G
Adv Immunol; 2016; 130():191-249. PubMed ID: 26923002
[TBL] [Abstract][Full Text] [Related]
10. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
12. Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer.
Che Y; Yang Y; Suo J; An Y; Wang X
Cancer Immunol Immunother; 2020 Dec; 69(12):2651-2664. PubMed ID: 32607768
[TBL] [Abstract][Full Text] [Related]
13. Current challenges for cancer vaccine adjuvant development.
Bowen WS; Svrivastava AK; Batra L; Barsoumian H; Shirwan H
Expert Rev Vaccines; 2018 Mar; 17(3):207-215. PubMed ID: 29372660
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Specific T Cell Activation in Malignant Brain Tumors.
Mohme M; Neidert MC
Front Immunol; 2020; 11():205. PubMed ID: 32117316
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical development of neoantigen vaccines.
Li L; Goedegebuure SP; Gillanders WE
Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
[TBL] [Abstract][Full Text] [Related]
17. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses.
Vermaelen K
Front Immunol; 2019; 10():8. PubMed ID: 30723469
[TBL] [Abstract][Full Text] [Related]
18. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic cancer vaccines.
Saxena M; van der Burg SH; Melief CJM; Bhardwaj N
Nat Rev Cancer; 2021 Jun; 21(6):360-378. PubMed ID: 33907315
[TBL] [Abstract][Full Text] [Related]
20. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
